Welcome to our dedicated page for Cochlear Ord Adr news (Ticker: CHEOY), a resource for investors and traders seeking the latest updates and insights on Cochlear Ord Adr stock.
The CHEOY news page aggregates coverage related to Cochlear plc Unsponsored ADR and the underlying company, Cochlear Limited (ASX: COH), which describes itself as the global leader in implantable hearing solutions. Here you can read about product launches, technology milestones, collaborations and recognition that shape the company’s role in hearing healthcare.
Recent news has featured the Cochlear Nucleus Nexa System, described by the company as the world’s first and only smart cochlear implant system with upgradeable implant firmware and internal memory in the implant. Other announcements highlight the Baha 7 Sound Processor and Baha SoundBand for bone conduction hearing, as well as the Osia System with the OSI300 Implant, which Cochlear reports is the first active bone conduction system to enable MRI at 3.0 Tesla without surgery.
Beyond product updates, Cochlear’s releases cover topics such as scholarship awards for Nucleus, Baha and Osia recipients in the United States and Canada, recognition in Newsweek rankings as the most trustworthy healthcare company, and partnerships like a multi-year research collaboration with Google and Australian Hearing Hub members to explore machine learning and other methods for hearing technologies.
Investors and observers following CHEOY can use this news feed to track how Cochlear presents its technology roadmap, clinical and policy engagement around hearing loss, and initiatives in customer support, such as visual assistance using augmented reality. Bookmark this page to review ongoing announcements that reflect the company’s activities in implantable hearing solutions and hearing health advocacy.
Cochlear Limited (ASX: CHEOY) has received FDA approval for the groundbreaking Cochlear™ Nucleus® Nexa™ System, the world's first smart cochlear implant system. The revolutionary system features upgradeable firmware on the implant, allowing recipients to access future innovations through firmware updates - an industry first.
The new Nucleus 8 Nexa Sound Processor with Power Compact rechargeable battery is 9% smaller and 12% lighter than its predecessor, making it the smallest sound processor with all-day battery life in the market. The system introduces innovative features including internal memory for storing patient hearing settings and Dynamic Power Management for optimized battery life.
The portfolio includes the Nucleus Nexa Implant, Nucleus Kanso® 3 Nexa Sound Processor, and Nucleus 8 Nexa Sound Processor, with legacy system users able to upgrade to the new Kanso 3 Sound Processor. Commercial availability is expected in late Summer 2025.
Cochlear (CHEOY) has been recognized as the most trustworthy healthcare company globally in Newsweek's 2024 World's Most Trustworthy Companies rankings. The assessment, conducted in partnership with Statista, evaluated companies based on customer, investor, and employee trust, gathering 269,000 evaluations from over 70,000 participants.
The global leader in implantable hearing solutions emphasizes customer-centric services through their Connected Care program, which includes rehabilitation programs, collaboration with audiologists, and access to a global community of Cochlear recipients. CEO Dig Howitt highlighted the company's commitment to customer service and support, along with initiatives focused on raising awareness about hearing loss and advocating for improved hearing care access.
Cochlear North America has announced eight winners of its 2025 Academic Scholarships on International Cochlear Implant Day. The recipients, all users of Cochlear™ devices, were selected for their leadership, humanity, and academic excellence.
Five students received the Graeme Clark Scholarship, now in its 23rd year: Emily E. (Speech-Language Pathology), Farah B. (Neuroscience), Grace F. (Occupational Therapy), Kaitlin C. (Pre-med), and Sophie G. (Education). Three students were awarded the Anders Tjellström Scholarship, in its 14th year: Dylan G. (Neuroscience/Psychology), Nathaniel G. (Government/Economics), and Zachary M. (Electrical Engineering/MBA).
Each scholarship recipient will receive $2,000 annually for up to four years at an accredited college or university, totaling $8,000 per student. The total scholarship funding for 2025 amounts to $64,000.
Cochlear, the global leader in implantable hearing solutions, highlights the Crosby family's journey during Healthy Aging Month. Herbert O. Crosby Junior (Butch), a former lineman and Vietnam veteran, experienced severe hearing loss due to prolonged exposure to loud noises. His daughter, Dr. Gina Crosby-Quinatoa, a Speech-Language Pathologist, recognized that her father could benefit from a cochlear implant.
In September 2022, Medicare expanded its coverage criteria for cochlear implants, allowing Butch to qualify for the procedure. He received a Cochlear™ Nucleus® 8 Sound Processor on December 28th, 2022, and was activated on January 23rd, 2023. The implant has significantly improved Butch's quality of life, enabling him to participate in social gatherings and enjoy conversations again.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cochlear, along with members of the Australian Hearing Hub, including National Acoustic Laboratories and Macquarie University, has initiated a groundbreaking collaboration with Google to develop innovative solutions to address hearing loss. This multi-year project will leverage artificial intelligence and machine learning to create personalized hearing devices, targeting environments with complex soundscapes. Additionally, experts have released the first international guidelines for cochlear implant eligibility, aiming to improve screening and referral practices. Currently, only 3 out of 100 adults who could benefit from these implants actually receive them, highlighting the need for better awareness and access.
FAQ
What is the current stock price of Cochlear Ord Adr (CHEOY)?
What is the market cap of Cochlear Ord Adr (CHEOY)?
